ERBB2 and breast carcinoma: The use of monoclonal antibodies has become a successful basic principle for highly selective targeting of extracellular receptor domains, and a prototypic example is the targeting of HER2 and the approval of trastuzumab for HER2-overexpressing breast cancer [1].